Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-04-04Clinical Trial Update: Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 trial evaluating fludarabine and rituximab with or without lenalidomide or cyclophosphamide in symptomatic chronic lymphocytic leuke…
-
CLINICAL_TRIALS trial_result · 2017-03-31Clinical Trial Update: Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia [Phase 3]
A Phase 3 trial evaluating idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia was terminated with…
-
CLINICAL_TRIALS trial_result · 2017-03-22Clinical Trial Update: An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia
An observational trial of Rituximab (MabThera/Rituxan) in relapsing or refractory chronic lymphocytic leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2017-03-21Clinical Trial Update: Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant [Phase 2]
Phase 2 study evaluating lenalidomide with or without rituximab in patients with relapsed or progressive chronic lymphocytic leukemia, small…
-
CLINICAL_TRIALS approval · 2017-03-20Clinical Trial Update: Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
An Early Access Program for ibrutinib in relapsed or refractory chronic lymphocytic leukemia has been approved for marketing.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-03-20Clinical Trial Update: Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL [Phase 2]
A Phase 2 trial evaluating dasatinib in combination with fludarabine and rituximab in relapsed or refractory chronic lymphocytic leukemia an…
-
CLINICAL_TRIALS research · 2017-03-16Clinical Trial Update: Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma [Phase 1, Phase 2]
This document describes a Phase 1/2 clinical trial evaluating competitive transfer of two αCD19-TCRz-CAR-T cell constructs (one with CD28 an…
-
CLINICAL_TRIALS research · 2017-03-13Clinical Trial Update: Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients [Phase 1, Phase 2]
This document provides an update on a Phase 1/2 clinical trial evaluating the combination of ruxolitinib and ibrutinib in patients with chro…
-
CLINICAL_TRIALS trial_result · 2017-03-13Clinical Trial Update: Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 2]
Phase II study of vismodegib in refractory or relapsed B-cell lymphoma or chronic lymphocytic leukemia has been terminated.
-
CLINICAL_TRIALS trial_result · 2017-03-09Clinical Trial Update: Tandem Auto-Allo Transplant for Lymphoma [Phase 2]
Phase 2 clinical trial update on tandem auto-allo transplantation for various lymphomas, with completed status and results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-03-03Clinical Trial Update: Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia [EARLY_Phase 1]
An early-phase 1 trial evaluated pretreatment with valproate before CD20-targeted immunotherapy in chronic lymphocytic leukemia.
-
CLINICAL_TRIALS trial_result · 2017-02-28Clinical Trial Update: CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy [Phase 1]
Phase 1 trial evaluating CART19 therapy for B-cell hematologic malignancies including various lymphomas and leukemias that are refractory or…
-
CLINICAL_TRIALS trial_result · 2017-02-27Clinical Trial Update: Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 study evaluating pentostatin, cyclophosphamide, and rituximab in patients with previously untreated chronic lymphocytic leukemia. Th…
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma [Phase 3]
Phase 3 trial comparing ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma com…
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) [Phase 3]
A Phase 3 study comparing dinaciclib to ofatumumab in patients with refractory chronic lymphocytic leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2017-02-15Clinical Trial Update: CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant [Phase 1, Phase 2]
This update covers a phase 1/2 clinical trial evaluating CD19 CAR T cells for B-cell malignancies in patients after allogeneic transplantati…
-
CLINICAL_TRIALS trial_result · 2017-02-15Clinical Trial Update: A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia [NA]
Duke University's clinical trial evaluating a quality-improvement approach to the management of chronic lymphocytic leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2017-02-09Clinical Trial Update: AMG 319 Lymphoid Malignancy FIH [Phase 1]
First-in-human Phase 1 clinical trial update for AMG 319 in lymphoid malignancies, including chronic lymphocytic leukemia and various lympho…
-
CLINICAL_TRIALS trial_result · 2017-02-08Clinical Trial Update: Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 trial evaluating pentostatin and rituximab, with or without cyclophosphamide, in previously untreated chronic lymphocytic leukemia (…
-
CLINICAL_TRIALS trial_result · 2017-02-08Clinical Trial Update: Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
A Phase 2 trial evaluating the combination of fludarabine, rituximab, and alemtuzumab in patients with chronic lymphocytic leukemia or small…
-
CLINICAL_TRIALS trial_result · 2017-02-08Clinical Trial Update: Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma [Phase 1, Phase 2]
This document provides an update on a Phase 1/2 clinical trial evaluating the combination of etanercept and rituximab in patients with chron…
-
FDA approval · 2017-02-06FDA Approved: BENDEKA — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Bendeka (bendamustine hydrochloride) submitted by Teva Pharmaceuticals USA, Inc., reflecting an …
-
CLINICAL_TRIALS trial_result · 2017-02-06Clinical Trial Update: A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated [Phase 1]
A Phase 1 dose-finding study evaluated CpG in previously treated patients with Chronic Lymphocytic Leukemia; the trial has completed.
-
CLINICAL_TRIALS trial_result · 2017-01-26Clinical Trial Update: Allogeneic Transplantation From Related Haploidentical Donors [Phase 2]
A Phase 2 clinical trial evaluating allogeneic transplantation from related haploidentical donors for blood cancers and leukemia has complet…
-
CLINICAL_TRIALS trial_result · 2017-01-19Clinical Trial Update: Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 trial evaluating denileukin diftitox in fludarabine-refractory B-cell chronic lymphocytic leukemia has completed.